Peter Goodhand is a leader in the global health sector as a senior executive and board member.
Peter played a key role in the creation of the Global Alliance for Genomics and Health
(GA4GH) and was appointed as its founding Executive Director in 2014, and as Chief Executive Officer in 2018. From May 2016 to April 2018, he also served as the President of the Ontario Institute for Cancer Research (OICR).
Prior to the GA4GH and OICR, he was the President and Chief Executive Officer of the Canadian Cancer Society, Canada's largest health charity. Before joining the charitable sector, Peter had a 20 year career in the global medical technology industry, including strategic leadership roles with multinational healthcare companies such as American Cyanamid and Johnson & Johnson; Board Chair and President of Canada’s Medical Device Industry association (MEDEC); and as the founding Managing Director and then Board Chair of the Health Technology Exchange (HTX).
Peter is currently a member of the Occupational Cancer Research Centre Steering
Committee, Co-chair of the Medical and Scientific Advisory Board of Global Genes, Co-chair of the International 100K+ Cohorts Consortium (IHCC), a member of the of the Global Genomic Medicine Collaboration (G2MC) Steering Committee, and a board member of Triphase. He chaired the Government of Canada’s Expert working group on the future of medical isotope production, and was a member of the Canadian delegation to the UN summit on noncommunicable diseases.